Paraneoplastic dermatomyositis and prostate cancer: Myopathy regression under cancer-directed therapy


Published: 29 July 2021
Abstract Views: 1831
PDF: 491
HTML: 10
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Prostate cancer is the second most frequent malignancy in men worldwide and the fifth leading cause of death. Dermatomyositis (DM) is a rare idiopathic inflammatory myopathy characterized by musculocutaneous manifestations. However, DM can also present as a paraneoplastic syndrome of an underlying neoplasm. We report a case of a 65-year-old man diagnosed with prostate adenocarcinoma in the setting of severe dysphagia, muscle weakness and a facial erythematous rash. At first, the DM-related symptoms resolved with the initial treatment for the underlying malignancy. Yet, they flared up as the tumor progressed. To sum up, DM is a rare systemic disorder with unknown etiology. There is a well-established association between DM and malignancy. Malignancy-headed therapy can improve DM manifestations and the recurrence of DM symptoms may act as an early warning of malignancy relapse.


Miranda Baleiras, M., Maduro, L., Vasques, C., Ferreira, F. ., Mesquita Pinto, M., & Martins, A. . (2021). Paraneoplastic dermatomyositis and prostate cancer: Myopathy regression under cancer-directed therapy. Dermatology Reports, 13(3). https://doi.org/10.4081/dr.2021.9262

Downloads

Download data is not yet available.

Citations